The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug ...

Proteintech has designed recombinant antibodies featuring the company's FcZero backbone, engineered to silence the Fc domain ...

Complementing its antibody offerings, BosterBio provides a range of ELISA kits designed for quantitative detection of ...

Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune statusSAN DIEGO, March 17, ...

Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth ...

Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...

Lundbeck has gained orphan drug designation (ODD) from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to ...

The Federal Circuit says that you must disclose and describe the prior art, or your Jepson claim is invalid. Obviously, this ...

After hours: March 17 at 4:05:11 PM EDT Loading Chart for FC ...

It performs an enzymatic modification method of IgG Fc glycans to perform conjugation. AGLink requires no prior engineering of the amino acid sequence, resulting in stable antibody conjugates ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...